Form 4: Elevation Oncology Director, Darcy Mootz, Acquires 35,000 Stock Options

Darcy Mootz, a director at Elevation Oncology, acquired 35,000 stock options on June 13, 2024, exercisable at $3.35.

Summary

• This Form 4 filing reports a transaction by Darcy Mootz, a director of Elevation Oncology, Inc.
• On June 13, 2024, Mootz acquired 35,000 stock options with an exercise price of $3.35.
• The options vest 100% on the one-year anniversary of the grant date, contingent on continued service to the Issuer.
• Following the transaction, Mootz directly owns 35,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating a director's acquisition of stock options, which is neither overtly positive nor negative.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a director's acquisition of stock options, which is a common form of executive compensation.

Stakeholder Impact

• The acquisition of stock options by a director could have a slightly positive impact on shareholders, as it aligns the director's interests with those of the shareholders.

Key Dates